Cargando…
Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation
TGF-β is essential for inducing systemic tumor immunosuppression; thus, blocking TGF-β can greatly enhance antitumor immunity. However, there are still no effective TGF-β inhibitors in clinical use. Here, we show that the clinically approved compound ursodeoxycholic acid (UDCA), by degrading TGF-β,...
Autores principales: | Shen, Yingying, Lu, Chaojie, Song, Zhengbo, Qiao, Chenxiao, Wang, Jiaoli, Chen, Jinbiao, Zhang, Chengyan, Zeng, Xianchang, Ma, Zeyu, Chen, Tao, Li, Xu, Lin, Aifu, Guo, Jufeng, Wang, Jianli, Cai, Zhijian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198048/ https://www.ncbi.nlm.nih.gov/pubmed/35701426 http://dx.doi.org/10.1038/s41467-022-31141-6 |
Ejemplares similares
-
Fas signaling-mediated T(H)9 cell differentiation favors bowel inflammation and antitumor functions
por: Shen, Yingying, et al.
Publicado: (2019) -
Comprehensive analysis to identify the influences of SARS-CoV-2 infections to inflammatory bowel disease
por: Zhang, Chengyan, et al.
Publicado: (2023) -
Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis
por: Wang, Zi-Long, et al.
Publicado: (2022) -
Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients
por: Wang, Zi-Long, et al.
Publicado: (2022) -
Red-Light-Activatable AND-Gated Antitumor Immunosuppressant
por: Zhou, Ziqi, et al.
Publicado: (2023)